<DOC>
	<DOCNO>NCT00400218</DOCNO>
	<brief_summary>Evaluate safety anti-hypertensive efficacy hyzaar ( R ) patient mild moderate essential hypertension .</brief_summary>
	<brief_title>Evaluate Safety Anti-Hypertensive Efficacy Hyzaar ( R ) In Patients With Mild To Moderate Essential Hypertension ( 0954A-323 )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Patient either receive high blood pressure monotherapy treatment Patient reach legal age time enter study Patients diagnose mild moderate essential high blood pressure high blood pressure condition diabetes cardiovascular disease take high blood pressure medication ( exclude diuretic ) , meet treatment goal Patient high level uric acid blood receive medication uric acid urine within 3 month prior enrollment Patients hypersensitive component study medication Patients hypersensitive sulfonamidederived drug Patients anuria ( hyzaar ( R ) recommend patient hepatic impairment severe renal impairment , creatinine clearance &lt; /= 30 ml/min ) Unstable diabetes ( hba1c &gt; 8 % ) , change diabetes medication study treatment . patient stable diabetes may enter study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>